| Identification | Back Directory | [Name]
LY 2874455 | [CAS]
1254473-64-7 | [Synonyms]
LY 2874455
LY2874455/LY-2874455
(R,E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)-ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)
(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)VINYL)-1H-PYRAZOL-1-YL)ETHANOL
(R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol
4-[(1E)-2-[5-[(1R)-1-(3,5-Dichloro-4-pyridinyl)ethoxy]-1H-indazol-3-yl]ethenyl]-1H-pyrazole-1-ethanol
(R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethan-1-ol
4-[(1E)-2-[5-[(1R)-1-(3,5-Dichloro-4-pyridinyl)ethoxy]-1H-indazol-3-yl]ethenyl]-1H-pyrazole-1-ethanol LY2874455 | [Molecular Formula]
C21H19Cl2N5O2 | [MDL Number]
MFCD22124884 | [MOL File]
1254473-64-7.mol | [Molecular Weight]
444.314 |
| Chemical Properties | Back Directory | [Boiling point ]
672.6±55.0 °C(Predicted) | [density ]
1.44 | [storage temp. ]
Store at -20°C | [solubility ]
≥44.4 mg/mL in DMSO; insoluble in H2O; ≥6.34 mg/mL in EtOH with gentle warming and ultrasonic | [form ]
solid | [pka]
12.93±0.40(Predicted) | [color ]
Pink to gray | [CAS DataBase Reference]
1254473-64-7 |
| Questions And Answer | Back Directory | [Description]
LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1. |
| Hazard Information | Back Directory | [Uses]
LY 2874455 is a pan-FGFR inhibitor which remain the focus of research for use in lung and bladder cancers. | [Biological Activity]
ly2874455 is a novel and potent fgfr inhibitor with ic50 value of 7 nm [1].fibroblast growth factor receptors (fgfrs) are receptors bind ligand of fgf family, which have a intracellular domain with tyrosine kinase activity. the binding of fgf triggers receptor dimerization and thus the activation of tyrosine kinase activity. activated tyrosine kinase phosphorylates various downstream factors to induce downstream signaling, including fgf substrate 2 (fgs2). this signaling pathway contributes to fgfr-mediated cell proliferation and migration, which are involved in tumor formation and progression.in huvecs cell line expressing fgfr1 and rt-112 cell line expressing fgfr3, ly2874455 treatment resulted in inhibition of fgf2 and fgf9 induced erk phosphorylation, which indicated the inhibitory activity of ly2874455 for fgfr1 and fgfr3 [1]. in snu-16 and kato-ш cell line, the inhibition of fgfr2 phosphorylation was also observed, which indicated a direct inhibition by ly2874455 [2]. additionally, when several multiple myeloma cancer cell lines were treated with lys2874455, the cell lines with chromosomal translocation that resulted in overexpression of fgfr3 were significantly more susceptible to the inhibition of ly2874455 [2]. it suggested fgfr was the specific target of ly2874455 inhibition.in rt-112, snu-16, opm-2 and nci-h460 xenograft tumor model, treatment of ly2874455 twice a day (1.5 mg/kg and 3 mg/kg) resulted in significant dose-dependent reduction of cellular level of phosphorylated fgfr, and also regression of tumor growth. it indicated the inhibitory activity of ly2874455 in vivo [2]. | [in vivo]
LY2874455 在所有 4 种测试模型中均表现出快速、稳健、剂量依赖性的肿瘤生长抑制作用。重要的是，该分子在 RT-112、SNU-16 和 OPM-2 肿瘤模型中导致肿瘤生长显著消退，尤其是在每天两次以 3 mg/kg 剂量给药时。此外，LY2874455 在 TED50 和 TED90 (1 和 3 mg/kg) 时显示出优秀的药代动力学特性。当在 RT-112 肿瘤异种移植模型中以间歇给药方案 (每天两次，服用 1 周，停药 1 周或每天两次，服用 2 天，停药 2 天) 进行测试时，LY2874455 也是有效的。当给大鼠服用 1 和 3 mg/kg 的 LY2874455 时，分别是大鼠心脏 IVTI 试验中获得的 TED50 (0.39 mg/kg) 的 2.6 倍和 7.7 倍，没有观察到血压的显著变化。然而，当给大鼠服用 10 mg/kg 的 LY2874455 (比 TED50 高 25.6 倍) 时，观察到动脉压显著升高[1]。 | [target]
FGFR1 | [IC 50]
FGFR1: 2.8 nM (IC50); FGFR2: 2.6 nM (IC50); FGFR3: 6.4 nM (IC50); FGFR4: 6 nM (IC50) | [storage]
Store at -20°C | [References]
[1] zhao, g s et al. , a novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. molecular cancer therapeutics. 2011, 10(11): 2200-2210. |
|
|